{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:06:54Z","timestamp":1793318814606,"version":"4.5.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.seminoncol.2025.152375","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:48:38Z","timestamp":1750938518000},"page":"152375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-5617","authenticated-orcid":false,"given":"Amr Ali Mohamed Abdelgawwad","family":"El-Sehrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9254-2380","authenticated-orcid":false,"given":"Mahmood Yaseen","family":"Mukhlif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysar Ashour","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subasini","family":"Uthirapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas","family":"Ballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1274-5117","authenticated-orcid":false,"given":"Abhayveer","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-5960","authenticated-orcid":false,"given":"V.","family":"Kavitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-0875","authenticated-orcid":false,"given":"Laxmidhar","family":"Maharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-4883","authenticated-orcid":false,"given":"Hayder","family":"Ridha-Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Remthan Hussein","family":"Al-Altememe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.seminoncol.2025.152375_bib0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152375_bib0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcancer.2021.06.016","article-title":"Prostate cancer cell heterogeneity and plasticity: insights from studies of genetically-engineered mouse models","volume":"82","author":"Li","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0004","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000519861","article-title":"Metastatic prostate cancer: treatment options","volume":"100","author":"Achard","year":"2022","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0006","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0007","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0008","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-3-319-91442-8_15","article-title":"Olaparib","volume":"211","author":"Bochum","year":"2018","journal-title":"Recent Results Cancer Res"},{"issue":"5\u20136","key":"10.1016\/j.seminoncol.2025.152375_bib0009","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"issue":"6330","key":"10.1016\/j.seminoncol.2025.152375_bib0010","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152375_bib0011","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0012","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jjco\/hyac015","article-title":"Olaparib in patients with mCRPC with homologous recombination repair gene alterations: Profound Asian subset analysis","volume":"52","author":"Matsubara","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"22","key":"10.1016\/j.seminoncol.2025.152375_bib0013","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus Olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152375_bib0015","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s11912-022-01337-6","article-title":"Resistance to poly (ADP-Ribose) polymerase inhibitors (PARPi): mechanisms and potential to reverse","volume":"24","author":"Washington","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152375_bib0016","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030361","article-title":"The epidemiology of prostate cancer","volume":"8","author":"Pernar","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-031-11836-4_15","article-title":"Prostate cancer epigenetic plasticity and enhancer heterogeneity: molecular causes, consequences and clinical implications","volume":"1390","author":"Kneppers","year":"2022","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152375_bib0018","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152375_bib0019","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on prostate cancer epidemiology and risk factors-A systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and mortality rates and trends\u2013an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0021","first-page":"228","article-title":"The risk factors of prostate cancer and its prevention: a literature review","volume":"48","author":"Perdana","year":"2016","journal-title":"Acta Med Indones"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2016.08.002","article-title":"Prostate cancer genetics: variation by race, ethnicity, and geography","volume":"27","author":"Rebbeck","year":"2017","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0023","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5114\/jhi.2020.96844","article-title":"Global burden of prostate cancer: regional disparities in incidence, mortality, and survival","volume":"6","author":"Dragomir","year":"2020","journal-title":"Journal of Health Inequalities"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0024","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0025","series-title":"Prostate cancer","article-title":"The epidemiology of prostate cancer","author":"Giona","year":"2021"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.56825","article-title":"Trends in prostate cancer incidence and mortality rates","volume":"8","author":"Van Blarigan","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0027","first-page":"39","article-title":"Histologic classification of prostate cancer","volume":"37","author":"Mikuz","year":"2015","journal-title":"Anal Quant Cytopathol Histpathol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122270","article-title":"Molecular heterogeneity in prostate cancer and the role of targeted therapy","volume":"336","author":"Khan","year":"2024","journal-title":"Life Sci"},{"issue":"Suppl 1","key":"10.1016\/j.seminoncol.2025.152375_bib0029","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1148\/rg.24si045502","article-title":"Complications of prostate cancer treatment: spectrum of imaging findings","volume":"24","author":"Yablon","year":"2004","journal-title":"Radiographics"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-030-32656-2_6","article-title":"Prostate cancer transcriptomic subtypes","volume":"1210","author":"Spratt","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032185","article-title":"Biomarkers of aggressive prostate cancer at diagnosis","volume":"24","author":"Boehm","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0032","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41588-018-0086-z","article-title":"Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets","volume":"50","author":"Wedge","year":"2018","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152375_bib0033","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eururo.2017.01.011","article-title":"Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns","volume":"72","author":"De Laere","year":"2017","journal-title":"Eur Urol"},{"issue":"94","key":"10.1016\/j.seminoncol.2025.152375_bib0034","doi-asserted-by":"crossref","first-page":"94ra72","DOI":"10.1126\/scitranslmed.3001970","article-title":"Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA","volume":"3","author":"Tomlins","year":"2011","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","article-title":"Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer","volume":"61","author":"Armstrong","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152375_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020802","article-title":"Exosomal liquid biopsy in prostate cancer: a systematic review of biomarkers for diagnosis, prognosis, and treatment response","volume":"26","author":"Hamid","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0037","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.mou.0000193384.39351.64","article-title":"Molecular biology of prostate-cancer pathogenesis","volume":"16","author":"Shand","year":"2006","journal-title":"Curr Opin Urol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0038","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1541-7786.MCR-22-0446","article-title":"Transcriptomes of prostate cancer with TMPRSS2:ERG and other ETS fusions","volume":"21","author":"Stopsack","year":"2023","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.canlet.2022.01.009","article-title":"ETS factors in prostate cancer","volume":"530","author":"Qian","year":"2022","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152375_bib0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/1940-6207.CAPR-22-0485","article-title":"Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer","volume":"16","author":"Gupta","year":"2023","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152375_bib0041","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s12253-018-0479-4","article-title":"C-MYC, HIF-1\u03b1, ERG, TKT, and GSTP1: an axis in prostate cancer?","volume":"25","author":"Boldrini","year":"2019","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0042","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152375_bib0043","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2174\/1389450111314040007","article-title":"The role of tumor suppressor dysregulation in prostate cancer progression","volume":"14","author":"Dean","year":"2013","journal-title":"Curr Drug Targets"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152375_bib0044","doi-asserted-by":"crossref","first-page":"431.e1","DOI":"10.1016\/j.urolonc.2016.05.018","article-title":"Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk","volume":"34","author":"Alvarez-Cubero","year":"2016","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152375_bib0045","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.trecan.2020.05.011","article-title":"Rothkamm K. DNA damage repair deficiency in prostate cancer","volume":"6","author":"Burdak-Rothkamm","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0046","article-title":"Contribution of inherited DNA-repair gene mutations to hormone-sensitive and castrate-resistant metastatic prostate cancer and implications for clinical outcome","volume":"3","author":"Yadav","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0047","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-3-319-95693-0_3","article-title":"Inflammation and prostate cancer","volume":"1095","author":"Tewari","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"11\u201312","key":"10.1016\/j.seminoncol.2025.152375_bib0048","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1080\/01635581.2020.1856889","article-title":"Obesity, inflammation, and advanced prostate cancer","volume":"73","author":"Olivas","year":"2021","journal-title":"Nutr Cancer"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152375_bib0049","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.acuro.2013.04.008","article-title":"Clinical significance of proliferative inflammatory atrophy in prostate biopsy","volume":"38","author":"Celma","year":"2014","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nucmedbio.2019.01.003","article-title":"Prostate cancer and inflammation: a new molecular imaging challenge in the era of personalized medicine","volume":"68-69","author":"Schillaci","year":"2019","journal-title":"Nucl Med Biol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0051","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1111\/ajco.13124","article-title":"Association between human papillomavirus infection and prostate cancer: a global systematic review and meta-analysis","volume":"15","author":"Moghoofei","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152375_bib0052","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152375_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122653","article-title":"Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0054","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ajpath.2023.12.003","article-title":"Androgen receptor-interacting proteins in prostate cancer development and therapy resistance","volume":"194","author":"Culig","year":"2024","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0056","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13238-020-00786-8","article-title":"Pioneer of prostate cancer: past, present and the future of FOXA1","volume":"12","author":"Teng","year":"2021","journal-title":"Protein Cell"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152375_bib0057","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1080\/03007995.2024.2395435","article-title":"Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) therapy: a systematic literature review","volume":"40","author":"Yan","year":"2024","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152375_bib0058","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/pros.23497","article-title":"The androgen receptor malignancy shift in prostate cancer","volume":"78","author":"Copeland","year":"2018","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0059","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030486","article-title":"DNA damage response in prostate cancer","volume":"9","author":"Schiewer","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152375_bib0060","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/2159-8290.CD-13-0679","article-title":"Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer","volume":"3","author":"Bartek","year":"2013","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152375_bib0061","article-title":"Connecting androgen receptor signaling and the DNA damage response: development of new therapies for advanced prostate cancer","volume":"4","author":"Thompson","year":"2017","journal-title":"Mol Cell Oncol"},{"issue":"18","key":"10.1016\/j.seminoncol.2025.152375_bib0062","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184441","article-title":"Androgen receptor splice variants contribute to the upregulation of DNA repair in prostate cancer","volume":"14","author":"Tolkach","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262453","article-title":"Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: a mathematical model","volume":"17","author":"Siewe","year":"2022","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152375_bib0064","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s43018-020-00125-0","article-title":"A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance","volume":"1","author":"Arriaga","year":"2020","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0065","doi-asserted-by":"crossref","first-page":"430","DOI":"10.56434\/j.arch.esp.urol.20227505.62","article-title":"Metastasic prostate cancer: predictive factors of earlier progression to castration-resistance","volume":"75","author":"Dellavedova","year":"2022","journal-title":"Arch Esp Urol"},{"issue":"23","key":"10.1016\/j.seminoncol.2025.152375_bib0066","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0067","first-page":"10352","article-title":"Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV","volume":"27","author":"Crawford","year":"2020","journal-title":"Can J Urol"},{"issue":"17","key":"10.1016\/j.seminoncol.2025.152375_bib0068","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0069","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00345-021-03893-1","article-title":"Active surveillance for intermediate-risk prostate cancer","volume":"40","author":"Nayan","year":"2022","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0070","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14030287","article-title":"The application of radiomics and AI to molecular imaging for prostate cancer","volume":"14","author":"Tapper","year":"2024","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0071","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00345-024-05242-4","article-title":"Partial prostatectomy for localized prostate cancer","volume":"42","author":"Wu","year":"2024","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0072","doi-asserted-by":"crossref","first-page":"283","DOI":"10.23736\/S2724-6051.20.04178-8","article-title":"A systematic review of nerve-sparing surgery for high-risk prostate cancer","volume":"73","author":"Morozov","year":"2021","journal-title":"Minerva Urol Nephrol"},{"issue":"19","key":"10.1016\/j.seminoncol.2025.152375_bib0073","doi-asserted-by":"crossref","first-page":"32237","DOI":"10.18632\/oncotarget.13332","article-title":"Robotic vs. retropubic radical prostatectomy in prostate cancer: a systematic review and an meta-analysis update","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0074","first-page":"122","article-title":"Current clinical challenges in prostate cancer","volume":"2","author":"Silberstein","year":"2013","journal-title":"Transl Androl Urol"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152375_bib0075","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0076","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0077","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CCO.0000000000000938","article-title":"Treatments and challenges in advanced prostate cancer","volume":"35","author":"Gourdin","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152375_bib0078","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094786","article-title":"Androgen receptor gene pathway upregulation and radiation resistance in oligometastatic prostate cancer","volume":"23","author":"Saxby","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152375_bib0079","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","article-title":"Metastatic castration-resistant prostate cancer: advances in treatment and symptom management","volume":"25","author":"Kulasegaran","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102726","article-title":"First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: applying clinical study findings to clinical practice in the United States","volume":"126","author":"McKay","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0081","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/157488410791498798","article-title":"Inducing synthetic lethality using PARP inhibitors","volume":"5","author":"Boss","year":"2010","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102651","article-title":"PARP-1 and its associated nucleases in DNA damage response","volume":"81","author":"Wang","year":"2019","journal-title":"DNA Rep (Amst)"},{"issue":"1\u20132","key":"10.1016\/j.seminoncol.2025.152375_bib0083","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152375_bib0084","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","article-title":"Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond","volume":"20","author":"Boussios","year":"2020","journal-title":"Drugs R D"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","article-title":"Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors","volume":"66","author":"Lord","year":"2015","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0086","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2020.102951","article-title":"DNA repair pathways as guardians of the genome: therapeutic potential and possible prognostic role in hematologic neoplasms","volume":"96","author":"Rahimian","year":"2020","journal-title":"DNA Repair"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2021.103211","article-title":"Transcription-coupled DNA double-strand break repair","volume":"109","author":"Guha","year":"2022","journal-title":"DNA Repair (Amst)"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152375_bib0089","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152375_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1568009623666230209121732","article-title":"Advances in ovarian cancer treatment beyond PARP inhibitors","volume":"23","author":"Aliyuda","year":"2023","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0092","doi-asserted-by":"crossref","first-page":"967","DOI":"10.21873\/anticanres.16241","article-title":"Homologous recombination defects and mutations in DNA damage response (DDR) genes besides BRCA1 and BRCA2 as breast cancer biomarkers for PARP inhibitors and other DDR targeting therapies","volume":"43","author":"Voutsadakis","year":"2023","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152375_bib0093","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"BRCAness, homologous recombination deficiencies, and synthetic lethality","volume":"83","author":"Murai","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152375_bib0094","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","article-title":"Synthetic lethality in cancer therapeutics: the next generation","volume":"11","author":"Setton","year":"2021","journal-title":"Cancer Discov"},{"issue":"8007","key":"10.1016\/j.seminoncol.2025.152375_bib0095","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152375_bib0096","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco-23-58","article-title":"Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis","volume":"12","author":"Olivares-Hern\u00e1ndez","year":"2023","journal-title":"Chin Clin Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152375_bib0097","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/path.2925","article-title":"PARP inhibition induces BAX\/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer","volume":"224","author":"Paul","year":"2011","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0098","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152375_bib0100","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.seminoncol.2025.152375_bib0101","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0102","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: results from the TAPUR study","volume":"7","author":"Yang","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0103","article-title":"Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer","volume":"5","author":"Taza","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0104","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152375_bib0105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential response to Olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations","volume":"76","author":"Marshall","year":"2019","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152375_bib0106","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"issue":"19","key":"10.1016\/j.seminoncol.2025.152375_bib0107","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, Olaparib, or Abiraterone\u202f+\u202fOlaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0108","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA approval summary: Olaparib in combination with Abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152375_bib0109","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","article-title":"A phase I study of combination Olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 3","key":"10.1016\/j.seminoncol.2025.152375_bib0110","article-title":"345\u2005Phase 3 study of combination pembrolizumab\u202f+\u202fOlaparib therapy versus enzalutamide\/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)","volume":"8","author":"Yu","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.seminoncol.2025.152375_bib0111","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0112","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/OTT.S499226","article-title":"The landscape of PARP inhibitors in solid cancers","volume":"18","author":"Muzzana","year":"2025","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0113","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17010008","article-title":"BRCA and beyond: impact on therapeutic choices across cancer","volume":"17","author":"Tan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0114","doi-asserted-by":"crossref","DOI":"10.1007\/s11010-025-05231-0","article-title":"Olaparib reverses prostate cancer resistance to Rapamycin by promoting macrophage polarization towards the M1 phenotype","author":"Ye","year":"2025","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152375_bib0115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrm.2017.20","article-title":"The HSP90 chaperone machinery","volume":"18","author":"Schopf","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152375_bib0116","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41580-023-00640-9","article-title":"Structural and functional complexity of HSP90 in cellular homeostasis and disease","volume":"24","author":"Chiosis","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"18","key":"10.1016\/j.seminoncol.2025.152375_bib0117","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189783","article-title":"Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic","volume":"22","author":"Ghose","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2025.02.004","article-title":"Early cost-effectiveness analysis of using whole genome sequencing for patients with castration-resistant prostate cancer","author":"Fu","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2024.12.008","article-title":"Incidence and risk of thromboembolic and cardiovascular adverse events with PARP inhibitor treatment in patients with metastatic castration-resistant prostate cancer: a systematic review and safety meta-analysis","volume":"72","author":"Maiorano","year":"2025","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40880-015-0047-1","article-title":"Targeted therapy: resistance and re-sensitization","volume":"34","author":"Chen","year":"2015","journal-title":"Chin J Cancer"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152375_bib0121","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and Immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152375_bib0122","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152375_bib0123","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.12998\/wjcc.v10.i11.3461","article-title":"Circulating tumor DNA genomic profiling reveals the complicated Olaparib-resistance mechanism in prostate cancer salvage therapy: a case report","volume":"10","author":"Yuan","year":"2022","journal-title":"World J Clin Cases"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152375_bib0124","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/apm.12084","article-title":"Frameshift mutation of a tumor suppressor gene PALB2 in gastric and colorectal cancers with microsatellite instability","volume":"121","author":"Kim","year":"2013","journal-title":"Apmis"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152375_bib0125","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/2767-9764.CRC-24-0339","article-title":"PINK1-Mediated mitochondrial activity confers Olaparib resistance in prostate cancer cells","volume":"4","author":"Schaaf","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152375_bib0126","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-21-0604","article-title":"Olaparib-induced senescence is bypassed through G2-M checkpoint override in Olaparib-resistant prostate cancer","volume":"21","author":"Lombard","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152375_bib0127","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1073\/pnas.96.7.3706","article-title":"GADD45 induction of a G2\/M cell cycle checkpoint","volume":"96","author":"Wang","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000066002","article-title":"Induction of hRAD9 is required for G2\/M checkpoint signal transduction in gastric cancer cells","volume":"70","author":"Hayashi","year":"2002","journal-title":"Pathobiology"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152375_bib0129","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.4161\/cc.24740","article-title":"Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override","volume":"12","author":"Beeharry","year":"2013","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1535-7163.MCT-16-0361","article-title":"Targeting Plk1 to enhance efficacy of Olaparib in castration-resistant prostate cancer","volume":"16","author":"Li","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0131","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4065580","article-title":"Expression of MUS81 mediates the sensitivity of castration-resistant prostate cancer to Olaparib","volume":"2022","author":"Gong","year":"2022","journal-title":"J Immunol Res"},{"issue":"16_Supplement","key":"10.1016\/j.seminoncol.2025.152375_bib0132","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.PRCA2017-IA18","article-title":"Abstract IA18: sensitivity and resistance biomarkers to PARP inhibitors in Mcrpc","volume":"78","author":"Mateo","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0133","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.2147\/OTT.S291267","article-title":"Targeting c-MET to enhance the efficacy of Olaparib in prostate cancer","volume":"14","author":"Wang","year":"2021","journal-title":"Onco Targets Ther"},{"issue":"24","key":"10.1016\/j.seminoncol.2025.152375_bib0134","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1111\/jcmm.17037","article-title":"MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM\/ATR and PI3K\/AKT pathways","volume":"25","author":"Zhou","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"23","key":"10.1016\/j.seminoncol.2025.152375_bib0135","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-20-2306","article-title":"Dual blockade of c-MET and the androgen receptor in metastatic castration-resistant prostate cancer: a phase I study of concurrent enzalutamide and crizotinib","volume":"26","author":"Tripathi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152375_bib0136","first-page":"2030","article-title":"STL127705 synergize with Olaparib in castration-resistant prostate cancer by inhibiting homologous recombination and non-homologous end-joining repair","volume":"13","author":"Sun","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0137","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1038\/s41467-024-51229-5","article-title":"CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts","volume":"15","author":"Curti","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0138","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.629266","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152375_bib0139","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.jmoldx.2021.08.010","article-title":"Predicted immunogenicity of CDK12 biallelic loss-of-function tumors varies across cancer types","volume":"23","author":"Elliott","year":"2021","journal-title":"J Mol Diagnos"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152375_bib0140","article-title":"An update on the prognostic and predictive serum biomarkers in metastatic prostate cancer","volume":"10","author":"Saxby","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152375_bib0141","doi-asserted-by":"crossref","first-page":"eabl9794","DOI":"10.1126\/sciadv.abl9794","article-title":"RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer","volume":"8","author":"Miao","year":"2022","journal-title":"Sci Adv"},{"issue":"15","key":"10.1016\/j.seminoncol.2025.152375_bib0142","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (Olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152375_bib0143","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/13543784.2024.2391828","article-title":"Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?","volume":"33","author":"Fenton","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152375_bib0144","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2967\/jnumed.120.249029","article-title":"First experiences with (177)Lu-PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients","volume":"62","author":"Prasad","year":"2021","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152375_bib0145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/0008-5472.CAN-23-1443","article-title":"Osteoclast cancer cell metabolic cross-talk confers PARP inhibitor resistance in bone metastatic breast cancer","volume":"84","author":"Fan","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0146","article-title":"Targeting Wnt signaling to overcome PARP inhibitor resistance","author":"Yamamoto","year":"2018","journal-title":"bioRxiv"},{"issue":"47","key":"10.1016\/j.seminoncol.2025.152375_bib0147","doi-asserted-by":"crossref","first-page":"28456","DOI":"10.18632\/oncotarget.25466","article-title":"Simultaneous delivery of Olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells","volume":"9","author":"Novohradsky","year":"2018","journal-title":"Oncotarget"},{"issue":"2_Supplement","key":"10.1016\/j.seminoncol.2025.152375_bib0148","article-title":"Abstract B48: prostate cancer pre-treatment with nanoformulated Olaparib overcomes radiation resistance","volume":"77","author":"ALvd","year":"2017","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152375_bib0149","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094624","article-title":"Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities","volume":"25","author":"Piombino","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152375_bib0150","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","article-title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","volume":"7","author":"Quigley","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0151","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152375_bib0152","first-page":"423","article-title":"Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel","volume":"19","author":"Kopczy\u0144ska","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152375_bib0153","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1245\/s10434-024-15453-z","article-title":"Role of MicroRNA-21 in prostate cancer progression and metastasis: molecular mechanisms to therapeutic targets","volume":"31","author":"Singh","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0154","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144995","article-title":"Role of microRNAs in the development, prognosis and therapeutic response of patients with prostate cancer","volume":"759","author":"Ghafouri-Fard","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.seminoncol.2025.152375_bib0155","article-title":"The miR-17-92 cluster: yin and Yang in human cancers","volume":"33","author":"Zhao","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"16_Supplement","key":"10.1016\/j.seminoncol.2025.152375_bib0156","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.PRCA2017-IA05","article-title":"Abstract IA05: emerging therapeutic strategies for androgen indifferent prostate cancer","volume":"78","author":"Beltran","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152375_bib0157","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3816\/CGC.2010.n.006","article-title":"Future directions in castrate-resistant prostate cancer therapy","volume":"8","author":"Antonarakis","year":"2010","journal-title":"Clin Genitourin Cancer"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T03:29:55Z","timestamp":1752636595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775425000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":156,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0093775425000673"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152375","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152375"}}